Biotechnology

Vland Biotech

Vland Biotech released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 345.05 M, actual EPS CNY 0.07

Vland Biotech released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 350.33 M, actual EPS CNY 0.0356

Vland Biotech released FY2025 earnings on April 24 After-Market (BJT), actual revenue CNY 1.366 B (forecast CNY 1.45 B), actual EPS CNY 0.28 (forecast CNY 0.33)

Vland Biotech to Release FY2025 Annual Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 1.45 B, EPS CNY 0.33

Vland Biotech to Release FY2026 Q1 Earnings on April 25 Pre-Market BJT

Vland Biotech released FY2025 Q3 earnings on October 28 Pre-Market (BJT), actual revenue CNY 363.6 M, actual EPS CNY 0.1223

Vland Biotech released FY2025 9 Months Earnings on October 28 Pre-Market (BJT), actual revenue CNY 1.016 B, actual EPS CNY 0.2319

Vland Biotech to Release FY2025 Q3 Earnings Report on October 29 Pre-Market BJT

Vland Biotech released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), with actual revenue of CNY 652.19 M and EPS of CNY 0.11

Vland Biotech released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 342 M, actual EPS CNY 0.0695

Vland Biotech FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

Weilann Bio Obtains New Veterinary Drug Registration Certificate for Fluconazole Lotion

Two New Veterinary Drugs Approved for Class III New Veterinary Drug by Welab

Welab Biological Obtained New Veterinary Drug Registration Certificate for Prednisolone Tablets

Welab Biotech Obtains New Veterinary Drug Registration Certificate

Welab Biotech sees steady revenue growth in 2024 and Q1 2025, with capacity layout largely completed

Weilans Bio Annual and Q1 Report Commentary: Revenue Pressure, Research Drives Growth

Blue Ocean Bio Announces Q1 2025 Revenue Growth and Net Profit Decline

Vland Biotech released FY2025 Q1 earnings on April 25 During-Market BJT, actual revenue CNY 310.2 M, actual EPS CNY 0.04

Vland Biotech released FY2024 earnings on April 25 After-Market (BJT), actual revenue CNY 1.321 B (forecast CNY 1.272 B), actual EPS CNY 0.25 (forecast CNY 0.335)

603739

According to the Zhitong Finance APP, Vland Biotech disclosed its third-quarter report for 2025, stating that the company achieved revenue of 1.016 billion yuan in the first three quarters, a year-on-year increase of 7.42%; net profit attributable to the parent company was 61.78 million yuan, a year-on-year increase of 51.24%; net profit excluding non-recurring items was 22.93 million yuan, a year-on-year decrease of 1.47%; basic earnings per share were 0.24 yuan

Zhitong

Vland Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 61.78 million yuan, a year-on-year increase of 51.24%

According to the Zhitong Finance APP, Vland Biotech announced that, after review by the Ministry of Agriculture and Rural Affairs, the company's wholly-owned subsidiary Qingdao Kangdien Animal Pharmaceutical Co., Ltd. and other units jointly applied for "Fluralaner Drops (for Dogs)" and "Fluralaner Drops (for Cats)" to be classified as new veterinary drugs of Category II, and the "New Veterinary Drug Registration Certificate" was recently issued

Vland Biotech's subsidiary receives registration certificates for two joint applications of new veterinary drugs

According to the Zhitong Finance APP, Vland Biotech disclosed its semi-annual report for 2025, reporting revenue of 652 million yuan, a year-on-year increase of 7.05%; net profit attributable to the parent company of 26.72 million yuan, a year-on-year decrease of 8.98%; net profit excluding non-recurring items of 16 million yuan, a year-on-year increase of 4.17%; and basic earnings per share of 0.11 yuan

Vland Biotech released its semi-annual performance report, with a net profit attributable to the parent company of 26.72 million yuan, a year-on-year decrease of 8.98%

Vland Biotech announced that the company and its wholly-owned subsidiaries, Qingdao Vland Zhi Chong Biotechnology Co., Ltd. and Qingdao Kangdian Animal Pharmaceutical Co., Ltd., along with other units, jointly applied for the "Mirtazapine Ointment" as a Category V new veterinary drug, and recently received the "New Veterinary Drug Registration Certificate." This product is mainly used to control weight loss in cats, developed jointly by the company and its wholly-owned subsidiaries with multiple units, with a total R&D investment of RMB 1.8622 million. The acquisition of the new veterinary drug certificate is expected to bring new performance growth points to the company's business

Vland Biotech: The company and its subsidiaries jointly applied for the registration certificate of the new veterinary drug for Mianping ointment, which has been approved

300238

688098

002688

Biological vaccine stocks strengthened, among which, Shen Lian Biomedical rose over 10%, Global Printing 10CM hit the daily limit, Guanhao Biotech and Sinovac Biotech rose over 7%, Saili Medical rose over 5%, Kanglao Weishi, Jinhe Biotechnology, and Vland Biotech rose over 4%, Yongshun Biotech, Dezhan Health, Junzheng Group, and Kanghua Biotech rose over 3%

Guanhao Biotech

Shen Lian Biomedical

Jinhe Biotechnology

300841

603718

688136

The animal vaccine sector continues to rise, with Shen Lian Biomedical up over 10%, and SDKX, Jinhe Biotechnology, Vland Biotech, Kanghua Biological, and HILE also following suit

Kanghua Biological

HILE

SDKX

The animal vaccine sector continues to rise, with Shen Lian Biomedical up over 10%

Vland Biotech has obtained a new veterinary drug registration certificate, approving its and its wholly-owned subsidiary's joint application for "Fluconazole Lotion" as a Class IV new veterinary drug. This medication is used to treat mild to moderate dermatophytosis in dogs caused by fungi

Vland Biotech obtains new veterinary drug registration certificate

Vland Biotech announced that it and its wholly-owned subsidiary have jointly applied for two new veterinary drug products that have obtained registration certificates. These include the "Porcine Pseudorabies Virus Gene-Deleted Inactivated Vaccine (CY-6 Strain)" and the "Chicken Newcastle Disease, Avian Influenza (H9 Subtype), and Avian Adenovirus Disease (Group 4 Type) Trivalent Inactivated Vaccine (LaSota Strain + TA Strain + LC Strain)", both approved as Class III new veterinary drugs

Vland Biotech: Two jointly filed products have obtained new veterinary drug registration certificates

Vland Biotech(603739.SH)